Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C96796
http://purl.obolibrary.org/obo/NCIT_C96796
|
|---|---|
| Preferred Name | Copanlisib |
| Definitions |
A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. |
|---|---|
| prefLabel | Copanlisib
|
| label | Copanlisib
|
| Has_Salt_Form | |
| PDQ_Closed_Trial_Search_ID | 653981
|
| code | C96796
|
| Has_Target | |
| prefixIRI | NCIT:C96796
|
| in_subset |
See more
See less
|
| Display_Name | Copanlisib
|
| Preferred_Name | Copanlisib
|
| FDA_UNII_Code | WI6V529FZ9
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Copanlisib
|
| CAS_Registry | 1032568-63-0
|
| NCI_Drug_Dictionary_ID | 653981
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 653981
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C3852004
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |